Patents by Inventor Yijun Huang

Yijun Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11373749
    Abstract: The present invention is related to improved methods for analysis of images of the vitreous and/or retina and/or choroid obtained by optical coherence tomography and to methods for making diagnoses of retinal disease based on the reflectivity profiles of various vitreous and/or retinal and/or choroidal layers of the retina.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: June 28, 2022
    Assignee: EyeKor, LLC
    Inventor: Yijun Huang
  • Publication number: 20220154154
    Abstract: The present invention relates to the technical field of biology, in particular to a phytase mutant, a preparation method therefor and an application thereof, a DNA molecule encoding the phytase mutant, a vector, and a host cell. The mutant provided by the present invention contains the substituent of an amino acid at at least one position selected from the following group: 36, 69, 89, 91, 111, 202, 213, 225, 238, 243, 253, 258, and 266. The heat resistance of the mutant is significantly improved, thereby facilitating the wide application of the phytase in feed.
    Type: Application
    Filed: February 11, 2020
    Publication date: May 19, 2022
    Applicant: QINGDAO VLAND BIOTECH GROUP CO., LTD
    Inventors: Xiuxiu WU, Yijun HUANG, Yang LIU, Xia ZHANG, Sida CHENG
  • Patent number: 11232557
    Abstract: Provided herein is technology relating to analysis of images and particularly, but not exclusively, to methods and systems for determining the area and/or volume of a region of interest using optical coherence tomography data. Some embodiments provide for determining the area and/or volume of a lesion in retinal tissue using three-dimensional optical coherence tomography data and a two-dimensional optical coherence tomography fundus image.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: January 25, 2022
    Assignee: EyeKor, LLC
    Inventor: Yijun Huang
  • Publication number: 20220010315
    Abstract: Provided is a method for producing washing enzyme having protease resistance. According to the method, the washing enzyme having resistance to protease is obtained by carrying out fusion expression on a gene of the washing enzyme with the gene of a protease inhibitory peptide, thereby facilitating maintaining the stability of various enzyme components in an enzyme-containing detergent, and improving the use effect of the detergent.
    Type: Application
    Filed: October 28, 2019
    Publication date: January 13, 2022
    Applicant: QINGDAO VLAND BIOTECH GROUP CO., LTD
    Inventors: Qing ZHANG, Zhibing CHEN, Yanping LIU, Yanjun TIAN, Wei XU, Yinan GUAN, Yijun HUANG, Jiahua LYU
  • Patent number: 10968439
    Abstract: The present invention relates to the technical field of protein engineering, and, in particular, to a xylanase mutant with improved heat tolerance. The present invention artificially introduces two or three unnatural disulfide bridges into xylanase by site-directed mutagenesis and obtains the mutants XynA1 and XynA2 with improved heat tolerance, especially the mutant XynA2 into which three disulfide bridges are introduced, achieving residual enzyme activity of 75% after treatment at 80° C. for 5 min, 72% higher than the residual enzyme activity of the mutant XynA1. The present invention further obtains, by screening, three mutation sites Q51N, H143K, and Q161F that can significantly increase the heat tolerance of mutants, and introduction of the mutation sites into the XynA1 and XynA2 xylanases, whether at a single point or a combination of two points or a combination of three points, can effectively improve the heat tolerance of the mutants.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: April 6, 2021
    Assignee: QINGDAO VLAND BIOTECH GROUP CO., LTD
    Inventors: Xiuxiu Wu, Chao Shao, Yijun Huang
  • Publication number: 20210060035
    Abstract: Disclosed is a use of 5?-androstane-3?,5,6?-triol, an analogue, a deuterated derivative, and a pharmaceutically acceptable salt thereof in manufacture of a medicament for the treatment of hemorrhagic stroke in a patient. The hemorrhagic stroke is intracerebral hemorrhage or subarachnoid hemorrhage.
    Type: Application
    Filed: December 28, 2018
    Publication date: March 4, 2021
    Applicant: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTD
    Inventors: Guangmei YAN, Yijun HUANG, Wei YIN, Suizhen LIN
  • Publication number: 20200368274
    Abstract: Methods for treatment of a multi-drug resistant (MDR) tumor in a subject are disclosed. The methods comprise administering to the subject in need of treatment a therapeutically effective amount of an anti-mycoplasma agent and/or an agent blocking the interaction between membrane protein P37 of mycoplasma and Annexin A2 of host cells of the subject, prior to, at the same time with, or after chemotherapy. Relevant pharmaceutical compositions, kits, uses are also disclosed.
    Type: Application
    Filed: August 8, 2017
    Publication date: November 26, 2020
    Applicant: SUN YAT-SEN UNIVERSITY
    Inventors: Yijun HUANG, Danyang LIU, Juncheng PAN, Yang HU, Zhu ZHU
  • Patent number: 10835539
    Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: November 17, 2020
    Assignee: Guangzhou Cellprotek Pharmaceutical Co., Ltd.
    Inventors: Wei Yin, Jiesi Chen, Guangmei Yan, Bingzheng Lu, Wenbo Zhu, Haiyan Hu, Pengxin Qiu, Yijun Huang, Jingxia Zhang
  • Publication number: 20200330483
    Abstract: Disclosed is use of 5?-androst-3?,5,6?-triol or an analogue, a deuterated compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cerebral small vessel disease in a patient. The cerebral small vessel disease is preferably cerebral microbleed. The cerebral microbleed is spontaneous cerebral microbleed, drug-related cerebral microbleed, or traumatic cerebral microbleed. The present invention demonstrates that these compounds significantly enhance the clearance of extravascular hemoglobin, and thus can be used to treat cerebral small vessel disease.
    Type: Application
    Filed: December 28, 2018
    Publication date: October 22, 2020
    Applicant: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTD
    Inventors: Guangmei YAN, Wei YIN, Longxiang SHENG, Bingzheng LU, Yijun HUANG, Suizhen LIN
  • Publication number: 20200239865
    Abstract: The present invention relates to the technical field of protein engineering, and, in particular, to a xylanase mutant with improved heat tolerance. The present invention artificially introduces two or three unnatural disulfide bridges into xylanase by site-directed mutagenesis and obtains the mutants XynA1 and XynA2 with improved heat tolerance, especially the mutant XynA2 into which three disulfide bridges are introduced, achieving residual enzyme activity of 75% after treatment at 80° C. for 5 min, 72% higher than the residual enzyme activity of the mutant XynA1. The present invention further obtains, by screening, three mutation sites Q51N, H143K, and Q161F that can significantly increase the heat tolerance of mutants, and introduction of the mutation sites into the XynA1 and XynA2 xylanases, whether at a single point or a combination of two points or a combination of three points, can effectively improve the heat tolerance of the mutants.
    Type: Application
    Filed: April 19, 2018
    Publication date: July 30, 2020
    Applicant: QINGDAO VLAND BIOTECH GROUP CO., LTD
    Inventors: Xiuxiu WU, Chao SHAO, Yijun HUANG
  • Publication number: 20200075155
    Abstract: The present invention is related to improved methods for analysis of images of the vitreous and/or retina and/or choroid obtained by optical coherence tomography and to methods for making diagnoses of retinal disease based on the reflectivity profiles of various vitreous and/or retinal and/or choroidal layers of the retina.
    Type: Application
    Filed: May 11, 2018
    Publication date: March 5, 2020
    Inventor: Yijun Huang
  • Publication number: 20190347796
    Abstract: Provided herein is technology relating to analysis of images and particularly, but not exclusively, to methods and systems for determining the area and/or volume of a region of interest using optical coherence tomography data. Some embodiments provide for determining the area and/or volume of a lesion in retinal tissue using three-dimensional optical coherence tomography data and a two-dimensional optical coherence tomography fundus image.
    Type: Application
    Filed: July 23, 2019
    Publication date: November 14, 2019
    Inventor: Yijun Huang
  • Publication number: 20190262358
    Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.
    Type: Application
    Filed: March 25, 2019
    Publication date: August 29, 2019
    Inventors: Wei Yin, Jiesi Chen, Guangmei Yan, Bingzheng Lu, Wenbo Zhu, Haiyan Hu, Pengxin Qiu, Yijun Huang, Jingxia Zhang
  • Patent number: 10360673
    Abstract: Provided herein is technology relating to analysis of images and particularly, but not exclusively, to methods and systems for determining the area and/or volume of a region of interest using optical coherence tomography data. Some embodiments provide for determining the area and/or volume of a lesion in retinal tissue using three-dimensional optical coherence tomography data and a two-dimensional optical coherence tomography fundus image.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: July 23, 2019
    Assignee: EyeKor, LLC
    Inventor: Yijun Huang
  • Patent number: 10357500
    Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: July 23, 2019
    Assignee: Guangzhou Cellprotek Pharmaceutical Co., Ltd.
    Inventors: Wei Yin, Jiesi Chen, Guangmei Yan, Bingzheng Lu, Wenbo Zhu, Haiyan Hu, Pengxin Qiu, Yijun Huang, Jingxia Zhang
  • Patent number: 10192042
    Abstract: The present disclosure provides a user verifying method, a terminal device, a server and a storage medium. The method may include: receiving, by a terminal device, a motion instruction from a server, and displaying the motion instruction on a display interface of the terminal device; obtaining sensed data of a gyroscope equipped in the terminal device and sending the sensed data to the server; determining, by the server, whether a motion trail of the terminal device constructed according to the sensed data meets a requirement of the motion instruction; and determining, by the server, that a user of the terminal device passes a user verification if the motion trail of the terminal device constructed according to the sensed data meets the requirement of the motion instruction. The method ensures that only human can accomplish the verifying process, which promotes the security of the user verification and improves the user experience.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: January 29, 2019
    Assignee: TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED
    Inventors: Jiwei Guo, Haibo Zuo, Luyi Lin, Yijun Huang
  • Publication number: 20170042909
    Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.
    Type: Application
    Filed: April 14, 2015
    Publication date: February 16, 2017
    Inventors: Wei Yin, Jiesi Chen, Guangmei Yan, Bingzheng Lu, Wenbo Zhu, Haiyan Hu, Pengxin Qiu, Yijun Huang, Jingxia Zhang
  • Publication number: 20160284103
    Abstract: Provided herein is technology relating to analysis of images and particularly, but not exclusively, to methods and systems for determining the area and/or volume of a region of interest using optical coherence tomography data. Some embodiments provide for determining the area and/or volume of a lesion in retinal tissue using three-dimensional optical coherence tomography data and a two-dimensional optical coherence tomography fundus image.
    Type: Application
    Filed: March 16, 2016
    Publication date: September 29, 2016
    Inventor: Yijun Huang
  • Publication number: 20160232338
    Abstract: The present disclosure provides a user verifying method, a terminal device, a server and a storage medium. The method may include: receiving, by a terminal device, a motion instruction from a server, and displaying the motion instruction on a display interface of the terminal device; obtaining sensed data of a gyroscope equipped in the terminal device and sending the sensed data to the server; determining, by the server, whether a motion trail of the terminal device constructed according to the sensed data meets a requirement of the motion instruction; and determining, by the server, that a user of the terminal device passes a user verification if the motion trail of the terminal device constructed according to the sensed data meets the requirement of the motion instruction. The method ensures that only human can accomplish the verifying process, which promotes the security of the user verification and improves the user experience.
    Type: Application
    Filed: April 18, 2016
    Publication date: August 11, 2016
    Inventors: JIWEI GUO, HAIBO ZUO, LUYI LIN, YIJUN HUANG
  • Patent number: 8567951
    Abstract: Certain diseases of the retina are diagnosed by circular profile analysis of retinal parameters, such as thickness. Retinal thickness around a user-defined circle on the retina is measured by three-dimensional optical coherence tomography or other ophthalmological techniques. Abnormally thin regions are identified by comparing a measured function of thickness vs. polar angle to a reference function of thickness vs. polar angle. A degree of abnormality is characterized by the ratio of the integral of the measured thickness function to the integral of the reference thickness function over the abnormally thin region, as specified by a range of polar angles.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: October 29, 2013
    Assignee: Topcon Medical Systems, Inc.
    Inventors: Yijun Huang, Tetsuyoshi Royama, Alexandre Kotchkin